cas 398489-26-4|| where to buy tert-butyl 3-oxoazetidine-1-carboxylate

Nom du produit:tert-butyl 3-oxoazetidine-1-carboxylate

IUPAC Name:tert-butyl 3-oxoazetidine-1-carboxylate

Unité d'emballage	Stock disponible	Prix($)
CM101906-100g	in stock	ǵǤ
CM101906-500g	in stock	ůŹů

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 398489-26-4 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:398489-26-4; Formule moléculaire:C8H13NO3; Point de fusion:-; Code SMILES:CC(C)(C)OC(=O)N1CC(=O)C1; Densité:

: Numéro de catalogue:CM101906; Poids moléculaire:171.2; Point d'ébullition:; N° Mdl:MFCD01861741; Stockage:Store at 2-8°C.

: Azetidines; Azetidines are an important class of saturated four-membered nitrogen-containing heterocyclic compounds. The research hotspots related to this structure mainly focus on two aspects: one is the research of pharmaceutical chemistry; the other is related to chiral azetidines, using rigid azetidine compounds as chiral ligands for asymmetric catalytic reactions. Many nitrogen-containing heterocycles play important roles in drug structures, and in many cases small structural changes can improve ligand selectivity and pharmacokinetic properties.; Where to buy Azetidines; Where to buy ADC-Cytotoxins? Chemenu Provide Azetidines with high quality and competitive price. Contact us Now.

: Alicyclic Heterocycles; When the ends of the chains are joined together into a ring, cyclic compounds result; such substances often are referred to as carbocyclic or alicyclic compounds. Substitution of one or more of the ring carbon atoms in the molecules of a carbocyclic compound with a heteroatom gives a heterocyclic compound.

: Emraclidine; Emraclidine is a novel, brain-penetrant, highly selective M4 receptor positive allosteric modulator(PAM) in development for the treatment of schizophrenia.
We believe emraclidine has the potential to provide a significant medical advancement as the muscarinic acetylcholine pathway has long been associated with mediation of neurotransmitter imbalance and psychosis. Emraclidine is the only selective M4 receptor PAM currently in clinical development.